27 completed, 10 terminated, 2 recruiting, 2 unknown. 25 Phase 2, 16 Phase 1, 7 Phase 3, 2 Early Phase 1, 1 Not applicable.
Follow interferon gamma-1b: new trials by email Literature Review of interferon gamma-1b trials Research Report on interferon gamma-1b
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial Tocilizumab, Baricitinib, Anakinra - Sepsis | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 2000 | 2026-07-09 | 2026-10-20 |
| Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation Interferon gamma-1b, Donor Leukocyte Infusion (DLI) - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 | Recruiting | Sawa Ito, MD | 57 | 2024-09-23 | 2026-08-11 |
| Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as standard of care, Antifungals as standard of care - Chronic Pulmonary Aspergillosis, Aspergillosis | Phase 2 | Active not recruiting | Manchester University NHS Foundation Trust | 50 | 2024-05-17 | 2026-08-18 |
| Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia Interferon Gamma-1B - Candidemia | Phase 2 | Completed | Radboud University Medical Center | 65 | 2022-03-31 | 2026-06-22 |
| IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation IFN-γ (interferon gamma-1b) injection - Myelodysplastic Syndromes, Myeloid Leukemia | Early Phase 1 | Completed | Sawa Ito, MD | 8 | 2021-03-08 | 2025-04-29 |
| Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Avelumab, Pembrolizumab - Other Skin | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 7 | 2019-07-03 | 2025-03-06 |
| Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease Interferon Gamma-1B - Chronic Granulomatous Disease | Completed | University of Colorado, Denver | 9 | 2018-05-16 | 2021-01-22 | |
| Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab - Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 28 | 2017-12-14 | 2023-10-25 |
| Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer Interferon-gamma (IFN-γ), Paclitaxel, Trastuzumab - Breast Cancer, Breast Cancer, Male | Phase 1 / Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 51 | 2017-06-23 | 2023-04-19 |
| Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer Autologous Monocytes + ACTIMMUNE + SYLATRON - Fallopian Tube Cancer, Ovarian Cancer | Phase 1 | Terminated | National Cancer Institute (NCI) | 18 | 2017-02-08 | 2026-01-08 |
| Effect of IFN-γ on Innate Immune Cells Administration of drug (Interferon-gamma 1-b) subcutaneously - Chronic Granulomatous Disease | Phase 1 | Completed | University of Colorado, Denver | 20 | 2016-07-01 | 2019-02-15 |
| Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia interferon γ-1b - Friedreich's Ataxia | Phase 3 | Completed | Amgen | 38 | 2016-06-28 | 2024-12-10 |
| ACTIMMUNE in Intermediate Osteopetrosis Interferon gamma-1b - Osteopetrosis | Phase 2 | Completed | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 5 | 2016-02-22 | 2024-10-22 |
| Use of ACTIMMUNE in Patients With ADO2 ACTIMMUNE - Autosomal Dominant Osteopetrosis Type 2 | Phase 2 | Completed | Indiana University | 12 | 2016-01-01 | 2021-01-08 |
| Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study Interferon γ-1b - Friedreich's Ataxia | Phase 3 | Completed | Amgen | 86 | 2015-12-25 | 2024-12-19 |
| Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Interferon γ-1b, Placebo - Friedreich's Ataxia | Phase 3 | Completed | Amgen | 92 | 2015-06-01 | 2024-12-19 |
| Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS) Interferon gamma-1b - Inherited Ophthalmic Diseases, Inherited Retinal Degeneration | Phase 1 / Phase 2 | Terminated | National Eye Institute (NEI) | 4 | 2015-01-14 | 2019-08-13 |
| DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors Single intratumoral injection of DNX-2401, Interferon-gamma - Glioblastoma or Gliosarcoma | Phase 1 | Completed | DNAtrix, Inc. | 37 | 2014-09-11 | 2018-07-16 |
| Interferon Gamma-1b in Friedreich Ataxia (FRDA) Interferon Gamma-1b - Friedreich Ataxia | Phase 2 | Completed | Children's Hospital of Philadelphia | 12 | 2013-08-01 | 2021-04-13 |
| Determining the Effect of Actimmune (Interferon Gamma 1b)Dose Titration on Flu-Like Symptoms in Healthy Volunteers interferon gamma 1b - Adverse Effects in the Therapeutic Use of Interferon | Phase 1 | Unknown | Vidara Therapeutics Research Ltd | 40 | 2013-07-01 | 2013-08-28 |
Showing 20 of 42. Sign in to see all of them.
HIV Infections (5) · Acquired Immunodeficiency Syndrome (4) · Friedreich Ataxia (4) · Fibrosis (3) · AIDS-Related Complex (2) · Carcinoma (2) · Cystic Fibrosis (2) · Granulomatous Disease, Chronic (2) · Idiopathic Pulmonary Fibrosis (2) · Leukemia, Myeloid, Acute (2) · Lung Diseases (2) · Lymphoma (2) · Macular Edema (2) · Myelodysplastic Syndromes (2) · Osteopetrosis (2)
InterMune (10) · Amgen (4) · National Cancer Institute (NCI) (4) · National Eye Institute (NEI) (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Sawa Ito, MD (2) · University of Colorado, Denver (2) · Accelerated Community Oncology Research Network (1) · Assistance Publique - Hôpitaux de Paris (1) · Children's Hospital of Philadelphia (1) · Children's Oncology Group (1) · DNAtrix, Inc. (1) · Fred Hutchinson Cancer Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Huntington Medical Research Institutes (1)
United States (37) · Australia (1) · Canada (1) · France (1) · Germany (1) · Greece (1) · Netherlands (1) · Peru (1) · Romania (1) · Switzerland (1) · United Kingdom (1)
Steven Porter, MD (3) · Daniel R. Ambruso, MD (2) · Allen R. Chen, MD, PhD, MHS (1) · Chris Kosmidis, MD (1) · Corey L (1) · David Lynch, MD, PhD (1) · Emily Y Chew, M.D. (1) · Frederick Lang, MD (1) · HW Murray (1) · Hatice Nida Sen, MD, MHSc (1)
PMID 15940636, PMID 15994231, PMID 16912304, PMID 17030856, PMID 19570573, PMID 2106474, PMID 24311766, PMID 2452123, PMID 24576196, PMID 28657784, PMID 30889272, PMID 31047956, PMID 3129521, PMID 32269142, PMID 33278077, PMID 33434107, PMID 34056870, PMID 35113934, PMID 35688625, PMID 35880940, PMID 38238788, PMID 40920799, PMID 42715345
P01CA225517 (1), P30CA015704 (1), U01CA062461 (1), U01CA154967 (1), UL1TR001082 (1)